IP Verse

Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof

EP3590949

MODERNATX, INC.
Application Number
EP19177059A
Filing Date
Oct 3, 2011
Status
Granted And Under Opposition
Apr 15, 2022
Grant Date
May 18, 2022
External Links
Slate, Register

Biblio Summary

The patent EP3590949B1 was granted on May 18, 2022 by Modernatx, Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 9 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHERNA IMMUNOTHERAPIES NVFeb 20, 2023ADMISSIBLE
MAIWALD GMBHFeb 20, 2023ADMISSIBLE
GLAXOSMITHKLINE BIOLOGICALS SAFeb 17, 2023ADMISSIBLE
PFIZER INC.Feb 17, 2023ADMISSIBLE
WITHERS & ROGERS LLPFeb 17, 2023ADMISSIBLE
KILBURN & STRODE LLPFeb 17, 2023WITHDRAWN
SANOFIOct 5, 2022ADMISSIBLE
PATENT BOUTIQUE LLPSep 27, 2022ADMISSIBLE
BIONTECH SESep 23, 2022ADMISSIBLE

More Opposed Patents of Modernatx, Inc.

The table below shows the patents of Modernatx, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3431485Engineered Nucleic Acids And Methods Of Use ThereofSep 4, 20242
EP3359670Methods For Therapeutic Administration Of Messenger Ribonucleic Acid DrugsFeb 14, 20241
EP3578652Ribonucleic Acid PurificationJul 12, 20231

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents